Intraluminal	O
Administration	O
of	O
Poly	O
I	O
:	O
C	O
Causes	O
an	O
Enteropathy	B-DS
That	O
Is	O
Exacerbated	O
by	O
Administration	O
of	O
Oral	O
Dietary	O
Antigen	O

Competing	O
Interests	O
:	O
E	O
.	O
F	O
.	O
V	O
.	O
receives	O
grant	O
support	O
from	O
Nestle	O
Research	O
Center	O
,	O
Switzerland	O
,	O
unrelated	O
to	O
this	O
study	O
.	O

The	O
remaining	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interest	O
exist	O
.	O

This	O
does	O
not	O
alter	O
the	O
authors	O
'	O
adherence	O
to	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RA	O
EV	O
FGC	O
.	O

Performed	O
the	O
experiments	O
:	O
RA	O
JJ	O
.	O

Analyzed	O
the	O
data	O
:	O
RA	O
EV	O
FGC	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CB	O
.	O

Wrote	O
the	O
paper	O
:	O
RA	O
EV	O
FGC	O
.	O

Systemic	O
administration	O
of	O
polyinosinic	O
:	O
polycytidylic	O
acid	O
(	O
poly	O
I	O
:	O
C	O
),	O
mimics	O
virally	O
-	O
induced	O
activation	O
of	O
TLR3	B-GP
signalling	O
causing	O
acute	O
small	O
intestine	O
damage	O
,	O
but	O
whether	O
and	O
how	O
mucosal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
causes	O
enteropathy	B-DS
is	O
less	O
clear	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
inflammatory	O
pathways	O
elicited	O
after	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
and	O
determine	O
acute	O
and	O
delayed	O
consequences	O
of	O
this	O
locally	O
induced	O
immune	O
activation	O
.	O

Intraluminal	O
poly	O
I	O
:	O
C	O
induced	O
rapid	O
mucosal	O
immune	O
activation	O
in	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
involving	O
IFNβ	B-GP
and	O
the	O
CXCL10	B-GP
/	O
CXCR3	B-GP
axis	O
,	O
that	O
may	O
drive	O
inflammation	O
towards	O
a	O
Th1	O
profile	O
.	O

Intraluminal	O
poly	O
I	O
:	O
C	O
also	O
caused	O
enteropathy	B-DS
and	O
gut	O
dysfunction	O
in	O
gliadin	B-GP
-	O
sensitive	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
,	O
and	O
this	O
was	O
prolonged	O
by	O
concomitant	O
oral	O
administration	O
of	O
gliadin	B-GP
.	O

Our	O
results	O
indicate	O
that	O
small	O
intestine	O
pathology	O
can	O
be	O
induced	O
in	O
mice	B-OG
by	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
and	O
that	O
this	O
is	O
exacerbated	O
by	O
subsequent	O
oral	O
delivery	O
of	O
a	O
relevant	O
dietary	O
antigen	O
.	O

Introduction	O

Detection	O
of	O
components	O
of	O
microorganisms	O
by	O
a	O
complex	O
system	O
of	O
pattern	O
recognition	O
receptors	O
leads	O
to	O
immune	O
host	O
defense	O
.	O

In	O
the	O
gut	O
,	O
home	O
to	O
1013	O
–	O
1014	O
resident	O
bacteria	B-OG
,	O
but	O
also	O
fungi	B-OG
and	O
viruses	B-OG
,	O
the	O
immune	O
mechanisms	O
elicited	O
have	O
a	O
critical	O
role	O
in	O
tissue	O
homeostasis	O
[	O
1	O
].	O

However	O
,	O
uncontrolled	O
activation	O
of	O
these	O
pathways	O
may	O
lead	O
to	O
pathology	O
,	O
as	O
demonstrated	O
in	O
studies	O
using	O
intraperitoneal	O
(	O
ip	O
)	O
administration	O
of	O
double	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
that	O
induces	O
overactivation	O
of	O
TLR3	B-GP
signalling	O
[	O
2	O
],	O
[	O
3	O
],	O
[	O
4	O
],	O
[	O
5	O
].	O

Polyinosinic	O
:	O
polycytidylic	O
acid	O
(	O
poly	O
I	O
:	O
C	O
)	O
is	O
a	O
synthetic	O
analogue	O
of	O
dsRNA	O
used	O
to	O
mimic	O
the	O
intermediates	O
of	O
replication	O
present	O
in	O
cells	O
infected	O
with	O
RNA	O
viruses	B-OG
and	O
some	O
DNA	O
viruses	B-OG
[	O
6	O
].	O

In	O
addition	O
to	O
TLR3	B-GP
,	O
dsRNA	O
sensors	O
include	O
two	O
cytoplasmic	O
receptors	O
,	O
retinoic	B-GP
acid	I-GP
-	I-GP
inducible	I-GP
gene	I-GP
I	I-GP
(	O
RIG	B-GP
-	I-GP
I	I-GP
)	O
and	O
melanoma	B-GP
differentiation	I-GP
-	I-GP
associated	I-GP
gene	I-GP
5	I-GP
(	O
MDA5	B-GP
)	O
[	O
7	O
].	O

NFκB	B-GP
and	O
IRF3	B-GP
/	O
7	O
are	O
the	O
dominant	O
nuclear	O
factors	O
involved	O
in	O
the	O
control	O
of	O
the	O
expression	O
of	O
inflammatory	O
cytokines	B-GP
and	O
chemokines	B-GP
and	O
Type	B-GP
I	I-GP
IFN	I-GP
,	O
respectively	O
,	O
upon	O
activation	O
by	O
dsRNA	O
[	O
8	O
].	O

McAllister	O
C	O
.	O
et	O
al	O
.	O
5	O
showed	O
that	O
signaling	O
pathways	O
activated	O
through	O
dsRNA	O
sensors	O
and	O
particularly	O
,	O
TLR3	B-GP
/	O
TRIF	B-GP
/	O
caspase	B-GP
8	I-GP
,	O
drive	O
intestinal	O
pathology	O
but	O
also	O
host	O
protection	O
during	O
viral	B-DS
infection	I-DS
.	O

However	O
,	O
the	O
role	O
of	O
locally	O
induced	O
,	O
rather	O
than	O
systemic	O
pathways	O
in	O
these	O
models	O
,	O
remain	O
unclear	O
.	O

More	O
importantly	O
there	O
is	O
a	O
scarcity	O
of	O
models	O
directly	O
relevant	O
to	O
small	O
intestinal	O
induction	O
of	O
pathology	O
and	O
gut	O
dysfunction	O
.	O

Epidemiological	O
studies	O
support	O
the	O
association	O
of	O
enteric	O
infections	B-DS
with	O
the	O
subsequent	O
development	O
of	O
inflammatory	O
or	O
functional	O
gastrointestinal	B-DS
disease	I-DS
[	O
9	O
],	O
[	O
10	O
].	O

Viral	B-DS
infections	I-DS
,	O
in	O
particular	O
enterovirus	B-OG
such	O
as	O
rotavirus	B-OG
,	O
have	O
been	O
suggested	O
to	O
increase	O
the	O
incidence	O
of	O
celiac	B-DS
disease	I-DS
(	O
CD	B-DS
),	O
a	O
permanent	O
intolerance	O
to	O
gluten	B-GP
that	O
occurs	O
in	O
genetically	O
susceptible	O
people	O
[	O
11	O
],	O
[	O
12	O
].	O

Case	O
reports	O
have	O
also	O
suggested	O
the	O
association	O
of	O
enteric	O
infections	B-DS
with	O
CD	B-DS
onset	O
[	O
13	O
].	O

Currently	O
,	O
the	O
underlying	O
mechanisms	O
that	O
support	O
this	O
association	O
are	O
poorly	O
understood	O
.	O

However	O
,	O
it	O
is	O
well	O
known	O
that	O
innate	O
immune	O
activation	O
generates	O
a	O
rapid	O
and	O
strong	O
anti	O
-	O
viral	O
response	O
,	O
which	O
essentially	O
involves	O
the	O
production	O
of	O
Type	B-GP
I	I-GP
IFNs	I-GP
and	O
other	O
components	O
of	O
the	O
inflammatory	O
response	O
.	O

The	O
link	O
among	O
enterovirus	B-DS
infection	I-DS
and	O
CD	B-DS
raises	O
the	O
hypothesis	O
that	O
Type	B-GP
I	I-GP
IFNs	I-GP
may	O
be	O
involved	O
in	O
loss	O
of	O
tolerance	O
to	O
gluten	B-GP
through	O
the	O
ability	O
to	O
promote	O
inflammation	O
and	O
an	O
strong	O
Th1	O
response	O
[	O
14	O
].	O

In	O
this	O
work	O
,	O
we	O
aimed	O
to	O
mimic	O
the	O
local	O
intestinal	O
immune	O
response	O
as	O
triggered	O
by	O
enteric	O
viral	B-DS
infection	I-DS
.	O

We	O
used	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
to	O
wild	O
type	O
mice	B-OG
and	O
evaluated	O
the	O
immediate	O
in	O
vivo	O
immune	O
and	O
pathological	O
mechanisms	O
triggered	O
at	O
the	O
small	O
intestinal	O
mucosa	O
.	O

We	O
also	O
investigated	O
the	O
potential	O
influence	O
of	O
this	O
initial	O
immune	O
activation	O
on	O
long	O
lasting	O
gut	O
functional	O
responses	O
to	O
administration	O
of	O
a	O
relevant	O
dietary	O
antigen	O
.	O

For	O
this	O
,	O
we	O
used	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
,	O
a	O
model	O
that	O
allows	O
in	O
vivo	O
evaluation	O
of	O
functional	O
and	O
immune	O
responses	O
to	O
gliadin	B-GP
,	O
the	O
storage	O
protein	O
in	O
cereals	O
[	O
15	O
].	O

Animal	B-OG
models	O
rarely	O
recapitulate	O
the	O
full	O
spectrum	O
of	O
human	B-OG
complex	O
diseases	O
.	O

Moreover	O
,	O
human	B-OG
diseases	O
often	O
express	O
different	O
clinical	O
phenotypes	O
.	O

Thus	O
the	O
usefulness	O
of	O
animal	B-OG
models	O
resides	O
in	O
mimicking	O
certain	O
aspects	O
of	O
disease	O
pathogenesis	O
in	O
order	O
to	O
generate	O
hypotheses	O
to	O
be	O
tested	O
in	O
clinical	O
trials	O
.	O

In	O
this	O
work	O
,	O
we	O
used	O
two	O
animal	B-OG
models	O
to	O
investigate	O
two	O
different	O
questions	O
.	O

First	O
,	O
the	O
effect	O
of	O
oral	O
poly	O
I	O
:	O
C	O
in	O
the	O
early	O
stages	O
of	O
the	O
mucosal	O
innate	O
immune	O
response	O
,	O
and	O
second	O
the	O
influence	O
of	O
the	O
administration	O
of	O
a	O
specific	O
dietary	O
antigen	O
in	O
preconditioned	O
mice	B-OG
.	O

We	O
observed	O
that	O
luminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
activated	O
the	O
innate	O
immune	O
response	O
and	O
caused	O
acute	O
enteropathy	B-DS
.	O

Administration	O
of	O
gliadin	B-GP
to	O
gliadin	B-GP
-	O
sensitive	O
mice	B-OG
previously	O
treated	O
with	O
poly	O
I	O
:	O
C	O
,	O
prolonged	O
gliadin	B-GP
-	O
induced	O
gut	O
dysfunction	O
.	O

We	O
propose	O
a	O
mucosally	O
-	O
driven	O
model	O
of	O
enteropathy	B-DS
by	O
poly	O
I	O
:	O
C	O
in	O
which	O
post	O
inflammatory	O
mechanisms	O
of	O
gastrointestinal	B-DS
disease	I-DS
can	O
be	O
investigated	O
.	O

Materials	O
and	O
Methods	O

Mice	B-OG

Eight	O
-	O
week	O
female	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
purchased	O
to	O
the	O
Animal	B-OG
Care	O
Facility	O
of	O
the	O
Faculty	O
of	O
Exact	O
and	O
Natural	O
Sciences	O
of	O
the	O
University	O
of	O
Buenos	O
Aires	O
.	O

Mice	B-OG
were	O
housed	O
in	O
plastic	O
cages	O
and	O
fed	O
ad	O
libitum	O
with	O
balanced	O
food	O
and	O
water	O
.	O

They	O
were	O
maintained	O
on	O
a	O
12h	O
light	O
/	O
darkness	O
cycle	O
and	O
acclimatized	O
to	O
the	O
surrounding	O
conditions	O
for	O
1	O
week	O
before	O
the	O
experimental	O
procedure	O
.	O

Transgenic	O
mice	B-OG
that	O
express	O
HLA	B-GP
-	O
DQ8	O
in	O
an	O
endogenous	O
MHC	B-GP
class	I-GP
II	I-GP
-	O
deficient	O
background	O
were	O
backcrossed	O
to	O
NOD	B-OG
mice	I-OG
for	O
10	O
generations	O
and	O
intercrossed	O
to	O
produce	O
congenic	O
NOD	B-OG
AB	I-OG
°	I-OG
DQ8	I-OG
mice	I-OG
[	O
16	O
].	O

Eight	O
-	O
to	O
10	O
-	O
wk	O
-	O
old	O
male	O
mice	B-OG
were	O
used	O
for	O
experiments	O
.	O

Mice	B-OG
were	O
weaned	O
and	O
maintained	O
on	O
a	O
low	O
-	O
fat	O
(	O
4	O
.	O
4	O
%),	O
gluten	B-GP
-	O
free	O
diet	O
.	O

The	O
original	O
breeding	O
pairs	O
of	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Chella	O
David	O
and	O
Dr	O
.	O
Joseph	O
Murray	O
from	O
Mayo	O
Clinic	O
,	O
Rochester	O
,	O
USA	O
,	O
and	O
subsequently	O
bred	O
in	O
specific	O
pathogen	O
-	O
free	O
conditions	O
at	O
McMaster	O
University	O
.	O

All	O
the	O
studies	O
were	O
performed	O
in	O
accordance	O
with	O
international	O
protocols	O
for	O
laboratory	O
animal	B-OG
care	O
(	O
Canadian	O
Council	O
on	O
Animal	B-OG
Care	O
).	O

Experiments	O
were	O
conducted	O
with	O
approval	O
from	O
the	O
McMaster	O
University	O
Animal	B-OG
Care	O
Committee	O
and	O
the	O
National	O
University	O
of	O
La	O
Plata	O
Ethic	O
Committee	O
.	O

Poly	O
I	O
:	O
C	O
treatment	O
and	O
oral	O
gavage	O

Mice	B-OG
were	O
kept	O
on	O
the	O
gluten	B-GP
free	O
diet	O
at	O
the	O
time	O
of	O
the	O
surgery	O
.	O

Poly	O
I	O
:	O
C	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
or	O
PBS	O
was	O
intraluminally	O
administrated	O
throughout	O
an	O
intestinal	O
microsurgery	O
that	O
allows	O
inject	O
the	O
stimuli	O
directly	O
in	O
the	O
lumen	O
of	O
small	O
intestine	O
.	O

Mice	B-OG
were	O
anaesthetized	O
with	O
Ketamine	O
80	O
mg	O
/	O
kg	O
of	O
weight	O
and	O
Xilacine	O
10	O
mg	O
/	O
kg	O
of	O
weight	O
.	O

Once	O
mice	B-OG
were	O
asleep	O
,	O
30μg	O
/	O
g	O
of	O
weight	O
of	O
poly	O
I	O
:	O
C	O
solution	O
in	O
PBS	O
were	O
injected	O
in	O
the	O
lumen	O
of	O
small	O
intestine	O
,	O
2	O
cm	O
after	O
the	O
stomach	O
,	O
to	O
avoid	O
the	O
enzymatic	O
degradation	O
of	O
the	O
poly	O
I	O
:	O
C	O
(	O
mainly	O
because	O
of	O
nuclease	B-GP
activity	O
from	O
pancreatic	O
enzymes	O
).	O

Control	O
mice	B-OG
receipted	O
only	O
PBS	O
in	O
the	O
lumen	O
.	O

After	O
the	O
surgery	O
,	O
a	O
fluid	O
replacement	O
was	O
done	O
and	O
mice	B-OG
were	O
strictly	O
monitored	O
until	O
they	O
were	O
able	O
to	O
walk	O
around	O
the	O
cage	O
.	O

A	O
group	O
of	O
mice	B-OG
was	O
sacrificed	O
after	O
3h	O
or	O
12h	O
post	O
-	O
treatment	O
with	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
,	O
and	O
samples	O
of	O
blood	O
and	O
small	O
intestine	O
were	O
collected	O
for	O
further	O
analysis	O
.	O

Other	O
group	O
of	O
mice	B-OG
was	O
orally	O
gavaged	O
with	O
5	O
mg	O
of	O
α	B-GP
-	I-GP
gliadin	I-GP
/	O
time	O
,	O
three	O
times	O
a	O
week	O
during	O
2	O
weeks	O
,	O
starting	O
at	O
24h	O
post	O
-	O
surgery	O
.	O
α	B-GP
-	I-GP
Gliadin	I-GP
(	O
by	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
dissolved	O
in	O
endotoxin	O
-	O
free	O
acetic	O
acid	O
0	O
.	O
02	O
M	O
.	O

Control	O
mice	B-OG
were	O
gavaged	O
with	O
the	O
acetic	O
acid	O
solution	O
only	O
(	O
Gluten	B-GP
-	O
free	O
diet	O
mice	B-OG
).	O

All	O
solutions	O
were	O
controlled	O
and	O
endotoxin	O
free	O
preparations	O
were	O
determined	O
using	O
E	O
-	O
TOXATE	O
endotoxin	O
kit	O
(	O
Sigma	O
).	O

Mice	B-OG
were	O
weighed	O
three	O
times	O
a	O
week	O
during	O
the	O
2	O
weeks	O
,	O
after	O
the	O
oral	O
gavage	O
.	O

Histologic	O
evaluation	O

Cross	O
-	O
sections	O
of	O
the	O
proximal	O
small	O
intestine	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
,	O
embedded	O
in	O
paraffin	O
,	O
and	O
stained	O
with	O
H	O
&	O
E	O
staining	O
for	O
histological	O
evaluation	O
by	O
using	O
a	O
Nikon	O
Eclipse	O
Ti	O
fluorescence	O
microscope	O
with	O
X	O
-	O
Cites	O
Series	O
120	O
Q	O
light	O
source	O
.	O

Images	O
were	O
taken	O
with	O
Nikon	O
Digital	O
Sight	O
DS	O
Ri1	O
camera	O
using	O
Nis	O
-	O
Elements	O
software	O
and	O
measurements	O
were	O
performed	O
using	O
Image	O
J	O
software	O
properly	O
calibrated	O
.	O

Two	O
sections	O
of	O
the	O
proximal	O
small	O
intestine	O
were	O
evaluated	O
for	O
evidence	O
of	O
inflammation	O
.	O

At	O
least	O
thirty	O
villus	O
-	O
to	O
-	O
crypt	O
ratios	O
were	O
measured	O
for	O
each	O
mouse	B-OG
in	O
a	O
blinded	O
fashion	O
.	O

Intraepithelial	O
lymphocytes	O
(	O
IELs	O
)	O
per	O
30	O
enterocytes	O
in	O
ten	O
randomly	O
chosen	O
villus	O
tips	O
were	O
counted	O
according	O
to	O
the	O
previously	O
described	O
methods	O
and	O
expressed	O
as	O
IEL	O
/	O
100	O
enterocytes	O
[	O
17	O
].	O

Histological	O
scores	O
were	O
obtained	O
from	O
the	O
small	O
intestinal	O
sections	O
stained	O
with	O
H	O
&	O
E	O
,	O
following	O
the	O
Park	O
-	O
Chiu	O
criteria	O
[	O
18	O
]:	O
0	O
,	O
normal	O
mucosa	O
;	O
1	O
,	O
subepithelial	O
space	O
at	O
villus	O
tips	O
;	O
2	O
,	O
extension	O
of	O
subepithelial	O
space	O
with	O
moderate	O
lifting	O
;	O
3	O
,	O
massive	O
lifting	O
down	O
sides	O
of	O
villi	O
,	O
some	O
denuded	O
tips	O
;	O
4	O
,	O
denuded	O
villi	O
,	O
dilated	O
capillaries	O
;	O
5	O
,	O
disintegration	O
of	O
lamina	O
propria	O
;	O
6	O
,	O
Crypt	O
layer	O
injury	O
;	O
7	O
,	O
transmucosal	O
infarction	O
;	O
8	O
,	O
transmural	O
infarction	O
.	O

Ussing	O
chambers	O

Two	O
sections	O
of	O
proximal	O
small	O
intestine	O
from	O
each	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mouse	I-OG
were	O
used	O
for	O
Ussing	O
chamber	O
experiments	O
as	O
described	O
previously	O
[	O
15	O
],	O
[	O
19	O
],	O
[	O
20	O
].	O

A	O
3	O
–	O
4	O
-	O
cm	O
piece	O
of	O
small	O
intestine	O
was	O
collected	O
(	O
3	O
cm	O
from	O
the	O
stomach	O
),	O
cut	O
into	O
two	O
sections	O
,	O
and	O
placed	O
in	O
Krebs	O
buffer	O
aerated	O
with	O
95	O
%	O
O2	O
and	O
5	O
%	O
CO2	O
(	O
pH	O
7	O
.	O
3	O
–	O
7	O
.	O
4	O
).	O

Each	O
segment	O
of	O
intestine	O
was	O
cut	O
open	O
along	O
the	O
mesenteric	O
border	O
to	O
form	O
a	O
flat	O
sheet	O
and	O
mounted	O
into	O
an	O
Ussing	O
chamber	O
.	O

The	O
chamber	O
exposed	O
0	O
.	O
7	O
cm2	O
of	O
tissue	O
surface	O
area	O
to	O
8	O
ml	O
of	O
circulating	O
oxygenated	O
Krebs	O
buffer	O
containing	O
10	O
mM	O
glucose	O
(	O
serosal	O
side	O
)	O
and	O
10	O
mM	O
mannitol	O
(	O
mucosal	O
side	O
)	O
maintained	O
at	O
37	O
°	O
C	O
.	O

Net	O
active	O
ion	O
transport	O
across	O
the	O
epithelium	O
was	O
measured	O
via	O
a	O
short	O
circuit	O
current	O
(	O
Isc	O
,	O
mA	O
)	O
injected	O
across	O
the	O
tissue	O
under	O
voltage	O
-	O
clamp	O
conditions	O
.	O

Tissue	O
conductance	O
(	O
the	O
passive	O
permeability	O
to	O
ions	O
)	O
was	O
calculated	O
using	O
Ohm	O
'	O
s	O
law	O
.	O

Baseline	O
Isc	O
(	O
mA	O
/	O
cm2	O
)	O
and	O
conductance	O
(	O
mS	O
/	O
cm2	O
)	O
were	O
recorded	O
at	O
equilibrium	O
,	O
20	O
min	O
after	O
mounting	O
small	O
intestine	O
sections	O
.	O

Cytokine	B-GP
analysis	O

The	O
presence	O
of	O
proinflammatory	O
cytokines	B-GP
in	O
serum	O
from	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
was	O
determined	O
using	O
a	O
Cytometric	O
Bead	O
Array	O
Inflammation	O
kit	O
(	O
BD	O
Biosciences	O
)	O
and	O
analyzed	O
using	O
BD	O
FACSarray	O
Bioanalyzer	O
System	O
(	O
BD	O
Biosciences	O
).	O

Real	O
Time	O
PCR	O

Small	O
Intestinal	O
samples	O
from	O
C57BL	O
/	O
6	O
and	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
were	O
stored	O
in	O
RNA	O
later	O
in	O
-	O
80	O
°	O
C	O
freezer	O
until	O
be	O
used	O
.	O

Tissues	O
were	O
disrupted	O
and	O
RNA	O
extraction	O
was	O
performed	O
using	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
).	O

cDNA	O
synthesis	O
was	O
performed	O
from	O
isolated	O
RNA	O
samples	O
(	O
2	O
-	O
5µg	O
),	O
using	O
iScript	O
Reverse	O
Transcription	O
Supermix	O
(	O
Bio	O
-	O
Rad	O
).	O

Real	O
Time	O
PCR	O
reaction	O
was	O
performed	O
with	O
SsoFast	O
EvaGreen	O
Supermix	O
(	O
Bio	O
-	O
Rad	O
)	O
using	O
the	O
adequate	O
forward	O
and	O
reverse	O
primers	O
and	O
the	O
iQ5	O
thermocycler	O
with	O
fluorescence	O
detection	O
(	O
Bio	O
-	O
Rad	O
).	O

Reactions	O
were	O
run	O
in	O
triplicate	O
.	O

The	O
Real	O
Time	O
PCR	O
protocol	O
was	O
:	O
Cycle	O
1	O
(	O
1X	O
)	O
95	O
°	O
C	O
for	O
10min	O
;	O
Cycle2	O
(	O
40X	O
)	O
60	O
°	O
C	O
for	O
1min	O
and	O
95	O
°	O
for	O
15sec	O
.	O

Primers	O
were	O
synthesized	O
as	O
it	O
was	O
previously	O
described	O
[	O
21	O
].	O

The	O
primer	O
sequences	O
are	O
provided	O
in	O
Table	O
1	O
.	O

The	O
geometric	O
mean	O
of	O
housekeeping	O
gene	O
HPRT	B-GP
was	O
used	O
as	O
an	O
internal	O
control	O
to	O
normalize	O
the	O
variability	O
in	O
expression	O
levels	O
.	O

All	O
results	O
were	O
expressed	O
as	O
a	O
fold	O
increase	O
of	O
PBS	O
and	O
PIC	O
treatment	O
versus	O
the	O
mean	O
of	O
PBS	O
treatment	O
in	O
every	O
time	O
point	O
(	O
2	O
−	O
ΔΔCt	O
method	O
).	O

Primers	O
used	O
for	O
quantitative	O
PCR	O
.	O

Gene	O

Forward	O

Reverse	O

HPRT	B-GP

CAATGCAAACTTTGCTTTCC	O

CAAATCCAACAAAGTCTGGC	O

MDA5	B-GP

CGATCCGAATGATTGATGCA	O

AGTTGGTCATTGCAACTGCT	O

RIG	B-GP
-	I-GP
I	I-GP

CAGACAGATCCGAGACACTA	O

TGCAAGACCTTTGGCCAGTT	O

TLR3	B-GP

GAAGATGATGCAGTCTTTCCA	O

CCTGTATCATATTCTACTCCTTGC	O

IFNβ	B-GP

AATGGAAAGATCAACCTCAC	O

AAGGCAGTGTAACTCTTCTG	O

CXCL10	B-GP

ATAGGGAAGCTTGAAATCATCC	O

TTCATCGTGGCAATGATCTC	O

CXCR3	B-GP

TGTAGTTGGGCTAGCTCGAACTT	O

ACCTGGATATATGCTGAGCTGTCA	O

TNFα	B-GP

CTCCCTCTCATCAGTTCTATGG	O

TTGAGAAGATGATCTGAGTGTG	O

IL	B-GP
-	I-GP
15	I-GP

CATCCATCTCGTGCTACTTGTGTT	O

CATCTATCCAGTTGGCCTCTGTTT	O

MCP1	B-GP

CTACAAGAGGATCACCAGCAG	O

TTCTGATCTCATTTGGTTCCG	O

CXCL2	B-GP

AAGATACTGAACAAAGGCAAGG	O

TTCTTTCTCTTTGGTTCTTCCG	O

IL	B-GP
-	I-GP
1β	I-GP

CGTTCCCATTAGACAACTGC	O

CTCATGGAGAATATCACTTGTTGG	O

IL	B-GP
-	I-GP
18	I-GP

GATCAAAGTGCCAGTGAACC	O

GATCTTGTTCTTACAGGAGAGG	O

IL	B-GP
-	I-GP
6	I-GP

CATGTTCTCTGGGAAATCGT	O

TATATCCAGTTTGGTAGCATCC	O

IFNγ	B-GP

CTGAGACAATGAACGCTACAC	O

TTTCTTCCACATCTATGCCAC	O

Bax	B-GP

TGCTACAGGGTTTCATCCAG	O

ATTGCTGTCCAGTTCATCTC	O

Bcl2	B-GP

GATCTCTGGTTGGGATTCCT	O

ACAACTTGCAATGAATCGGG	O

Fluorescence	O
microscopy	O

Small	O
intestinal	O
sections	O
from	O
PBS	O
-	O
and	O
PIC	O
-	O
treated	O
mice	B-OG
were	O
deparaffinized	O
and	O
an	O
immunofluorescence	O
protocol	O
was	O
performed	O
.	O

Antigenicity	O
recovery	O
was	O
performed	O
using	O
Antigen	O
Retrieval	O
AR	O
-	O
10	O
Solution	O
(	O
BioGenex	O
).	O

After	O
blocking	O
with	O
2	O
%	O
goat	B-OG
serum	O
,	O
goat	B-OG
anti	O
-	O
IL	B-GP
-	I-GP
15	I-GP
IgG	B-GP
antibody	O
(	O
R	O
&	O
D	O
)	O
was	O
added	O
in	O
a	O
concentration	O
of	O
2	O
µg	O
/	O
ml	O
for	O
1h	O
.	O

Alexa488	O
donkey	B-OG
anti	O
-	O
goat	B-OG
antibody	O
(	O
Molecular	O
Probes	O
)	O
in	O
a	O
concentration	O
of	O
10	O
µg	O
/	O
ml	O
was	O
added	O
for	O
1h	O
.	O

Nuclei	O
were	O
stained	O
with	O
propidium	O
iodide	O
at	O
1	O
µg	O
/	O
ml	O
for	O
15	O
minutes	O
.	O

Images	O
were	O
obtained	O
and	O
analyzed	O
in	O
a	O
TCS	O
SP5	O
Confocal	O
Microscope	O
combined	O
with	O
Leica	O
LAS	O
AF	O
software	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
performed	O
with	O
GraphPad	O
Prism	O
software	O
.	O

For	O
more	O
than	O
two	O
treatment	O
groups	O
,	O
an	O
ANOVA	O
with	O
a	O
Bonferroni	O
post	O
hoc	O
test	O
for	O
multiple	O
comparisons	O
was	O
used	O
.	O

When	O
two	O
groups	O
were	O
compared	O
,	O
an	O
unpaired	O
t	O
test	O
was	O
used	O
;	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Data	O
are	O
displayed	O
as	O
mean	O
±	O
SEM	O
.	O

Results	O

Intraluminal	O
poly	O
I	O
:	O
C	O
induces	O
histological	O
changes	O
in	O
the	O
small	O
intestinal	O
mucosa	O

We	O
first	O
evaluated	O
the	O
capacity	O
of	O
poly	O
I	O
:	O
C	O
delivered	O
at	O
the	O
mucosal	O
site	O
to	O
induce	O
enteropathy	B-DS
in	O
wild	O
type	O
mice	B-OG
.	O

Intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
to	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
produced	O
severe	O
enteropathy	B-DS
.	O

At	O
12h	O
post	O
poly	O
I	O
:	O
C	O
,	O
we	O
observed	O
shortening	O
and	O
widening	O
of	O
villi	O
,	O
edema	O
,	O
and	O
increased	O
cell	O
infiltration	O
in	O
the	O
lamina	O
propria	O
(	O
LP	O
).	O

Using	O
H	O
&	O
E	O
staining	O
edema	O
,	O
dilated	O
capillaries	O
and	O
interstitial	O
spaces	O
were	O
observed	O
in	O
intestinal	O
villi	O
(	O
Figure	O
1A	O
).	O

Furthermore	O
,	O
V	O
/	O
C	O
ratios	O
were	O
decreased	O
,	O
while	O
the	O
number	O
of	O
IELs	O
and	O
global	O
histological	O
score	O
increased	O
compared	O
to	O
PBS	O
-	O
treated	O
mice	B-OG
(	O
Figure	O
1B	O
).	O

At	O
72h	O
post	O
poly	O
I	O
:	O
C	O
,	O
there	O
was	O
partial	O
recovery	O
of	O
villus	O
-	O
to	O
-	O
crypt	O
(	O
V	O
/	O
C	O
)	O
ratios	O
.	O

In	O
contrast	O
to	O
control	O
mice	B-OG
,	O
morphometric	O
parameters	O
remained	O
altered	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
(	O
Figure	O
1C	O
).	O

As	O
expected	O
,	O
the	O
surgical	O
procedure	O
altered	O
intestinal	O
histology	O
.	O

However	O
,	O
this	O
change	O
was	O
transient	O
,	O
and	O
control	O
mice	B-OG
exhibited	O
a	O
faster	O
recovery	O
after	O
treatment	O
.	O

We	O
also	O
tested	O
whether	O
molecular	O
weight	O
of	O
poly	O
I	O
:	O
Cs	O
influenced	O
inflammation	O
and	O
mucosal	O
damage	O
.	O

We	O
did	O
not	O
detect	O
significant	O
differences	O
among	O
the	O
tested	O
poly	O
I	O
:	O
Cs	O
(	O
Figure	O
S1	O
),	O
and	O
therefore	O
the	O
remaining	O
experiments	O
were	O
carried	O
out	O
using	O
the	O
commonly	O
used	O
commercial	O
poly	O
I	O
:	O
C	O
.	O

Intraluminal	O
poly	O
I	O
:	O
C	O
induces	O
enteropathy	B-DS
.	O

Representative	O
H	O
&	O
E	O
stained	O
sections	O
of	O
proximal	O
small	O
intestine	O
of	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
after	O
12hs	O
and	O
72hs	O
of	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
(	O
A	O
).	O

Morphological	O
analysis	O
of	O
small	O
intestine	O
from	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
:	O
villus	O
-	O
to	O
-	O
crypt	O
(	O
V	O
/	O
C	O
)	O
ratio	O
,	O
number	O
of	O
IELs	O
and	O
histological	O
score	O
after	O
12h	O
(	O
B	O
)	O
and	O
72h	O
(	O
C	O
)	O
(	O
Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
).	O

Inflammatory	O
mediators	O
and	O
receptors	O
MDA5	B-GP
,	O
RIGI	B-GP
and	O
TLR3	B-GP
are	O
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
in	O
small	O
intestine	O

We	O
next	O
explored	O
the	O
signaling	O
pathways	O
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
.	O

For	O
this	O
we	O
analyzed	O
the	O
kinetics	O
of	O
expression	O
of	O
inflammatory	O
mediators	O
and	O
three	O
receptors	O
for	O
poly	O
I	O
:	O
C	O
in	O
a	O
time	O
-	O
course	O
experiment	O
using	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
.	O

In	O
the	O
small	O
intestine	O
,	O
there	O
was	O
a	O
rapid	O
and	O
strong	O
increment	O
of	O
IFNβ	B-GP
2h	O
after	O
treatment	O
,	O
while	O
CXCL10	B-GP
and	O
TNFα	B-GP
peaked	O
4h	O
after	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
(	O
Figure	O
2A	O
).	O

Analysis	O
of	O
expression	O
of	O
proinflammatory	O
cytokines	B-GP
such	O
as	O
IL	B-GP
-	I-GP
18	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
15	I-GP
and	O
IFNγ	B-GP
,	O
chemokines	B-GP
such	O
as	O
MCP1	B-GP
and	O
CXCL2	B-GP
,	O
and	O
anti	O
-	O
and	O
pro	O
-	O
apoptotic	O
molecules	O
Bcl	B-GP
-	I-GP
2	I-GP
and	O
Bax	B-GP
,	O
respectively	O
,	O
did	O
not	O
show	O
any	O
differences	O
between	O
groups	O
(	O
data	O
not	O
shown	O
).	O
Since	O
recognition	O
of	O
poly	O
I	O
:	O
C	O
is	O
mediated	O
by	O
TLR3	B-GP
,	O
MDA5	B-GP
and	O
RIGI	B-GP
and	O
their	O
expressions	O
are	O
modulated	O
by	O
poly	O
I	O
:	O
C	O
,	O
we	O
evaluated	O
whether	O
the	O
expression	O
of	O
these	O
receptors	O
were	O
induced	O
in	O
the	O
small	O
intestine	O
of	O
treated	O
mice	B-OG
.	O

The	O
time	O
course	O
experiment	O
showed	O
that	O
MDA5	B-GP
,	O
RIGI	B-GP
and	O
TLR3	B-GP
mRNA	O
were	O
similarly	O
upregulated	O
in	O
small	O
intestine	O
by	O
intraluminal	O
injection	O
of	O
poly	O
I	O
:	O
C	O
.	O

Expression	O
of	O
the	O
three	O
receptors	O
peaked	O
6h	O
post	O
-	O
treatment	O
(	O
Figure	O
2B	O
).	O

Furthermore	O
,	O
we	O
analyzed	O
the	O
protein	O
expression	O
of	O
IL	B-GP
-	I-GP
15	I-GP
,	O
obtaining	O
no	O
relevant	O
differences	O
among	O
poly	O
I	O
:	O
C	O
and	O
PBS	O
treatments	O
after	O
12h	O
(	O
data	O
not	O
shown	O
).	O

Intraluminal	O
poly	O
I	O
:	O
C	O
generates	O
a	O
proinflammatory	O
response	O
and	O
the	O
induction	O
of	O
MDA5	B-GP
,	O
RIG	B-GP
-	I-GP
I	I-GP
and	O
TLR3	B-GP
mRNA	O
expression	O
in	O
small	O
intestine	O
.	O

Real	O
Time	O
-	O
PCR	O
analysis	O
of	O
small	O
intestinal	O
samples	O
from	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
after	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
was	O
performed	O
.	O

Plots	O
shows	O
mRNA	O
expression	O
after	O
2	O
to	O
12h	O
of	O
poly	O
I	O
:	O
C	O
(	O
black	O
dots	O
)	O
or	O
PBS	O
(	O
empty	O
dots	O
)	O
treatment	O
.	O

IFNβ	B-GP
,	O
CXCL10	B-GP
,	O
and	O
TNFα	B-GP
mRNA	O
expression	O
(	O
A	O
).	O

MDA5	B-GP
,	O
RIG	B-GP
-	I-GP
I	I-GP
,	O
and	O
TLR3	B-GP
mRNA	O
expression	O
(	O
B	O
).	O

All	O
values	O
were	O
normalized	O
with	O
the	O
housekeeping	O
mRNA	O
expression	O
(	O
HPRT	B-GP
).	O

Results	O
were	O
expressed	O
as	O
fold	O
increase	O
of	O
PBS	O
and	O
poly	O
I	O
:	O
C	O
treatment	O
versus	O
the	O
mean	O
of	O
PBS	O
treatment	O
in	O
every	O
time	O
point	O
(	O
2	O
-	O
ΔΔCt	O
method	O
).	O

Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
,	O
poly	O
I	O
:	O
C	O
treated	O
mice	B-OG
versus	O
PBS	O
control	O
in	O
the	O
same	O
time	O
point	O
.	O

Inflammatory	O
response	O
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
in	O
the	O
small	O
intestine	O
of	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG

The	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mouse	I-OG
represents	O
one	O
useful	O
model	O
of	O
gluten	B-GP
sensitivity	O
[	O
15	O
].	O

Nevertheless	O
,	O
the	O
model	O
has	O
particular	O
phenotypes	O
given	O
by	O
the	O
DQ8	O
restriction	O
and	O
the	O
NOD	O
background	O
[	O
22	O
].	O

Thus	O
,	O
prior	O
to	O
gliadin	B-GP
antigen	O
administration	O
,	O
we	O
first	O
examined	O
in	O
detail	O
the	O
immune	O
responses	O
to	O
poly	O
I	O
:	O
C	O
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Indeed	O
,	O
poly	O
I	O
:	O
C	O
caused	O
severe	O
mucosal	O
damage	O
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
characterized	O
by	O
cell	O
infiltration	O
of	O
the	O
LP	O
,	O
edema	O
and	O
shortening	O
of	O
villi	O
at	O
12h	O
post	O
-	O
treatment	O
(	O
Figure	O
3A	O
).	O

Morphometric	O
parameters	O
revealed	O
marked	O
reduction	O
in	O
the	O
V	O
/	O
C	O
ratio	O
in	O
poly	O
I	O
:	O
C	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Also	O
,	O
IELs	O
numbers	O
and	O
histological	O
scores	O
were	O
higher	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
than	O
in	O
control	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
(	O
Figure	O
3B	O
).	O

Intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
induces	O
enteropathy	B-DS
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Representative	O
H	O
&	O
E	O
-	O
stained	O
sections	O
of	O
the	O
proximal	O
small	O
intestine	O
in	O
PBS	O
and	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
at	O
12h	O
post	O
-	O
treatment	O
(	O
A	O
).	O

Morphological	O
analysis	O
of	O
small	O
intestine	O
from	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
:	O
villus	O
-	O
to	O
-	O
crypt	O
(	O
V	O
/	O
C	O
)	O
ratio	O
,	O
number	O
of	O
IELs	O
and	O
histological	O
score	O
after	O
12h	O
.	O

Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
(	O
B	O
).	O

We	O
found	O
that	O
IFNβ	B-GP
mRNA	O
expression	O
was	O
increased	O
in	O
the	O
small	O
intestinal	O
mucosa	O
of	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
at	O
3h	O
post	O
-	O
poly	O
I	O
:	O
C	O
compared	O
to	O
controls	O
(	O
Figure	O
4	O
).	O

A	O
40	O
-	O
fold	O
increment	O
in	O
CXCL10	B-GP
mRNA	O
was	O
observed	O
at	O
3	O
h	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
.	O

At	O
12	O
hours	O
,	O
CXCL10	B-GP
levels	O
remained	O
higher	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
than	O
in	O
controls	O
.	O

The	O
cytoplasmic	O
pattern	O
recognition	O
receptors	O
for	O
poly	O
I	O
:	O
C	O
,	O
MDA5	B-GP
and	O
RIG	B-GP
-	I-GP
I	I-GP
,	O
were	O
also	O
induced	O
in	O
the	O
small	O
mucosa	O
of	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Expression	O
of	O
both	O
receptors	O
was	O
increased	O
at	O
3h	O
,	O
but	O
was	O
higher	O
at	O
12	O
h	O
after	O
treatment	O
.	O

The	O
upregulation	O
of	O
these	O
receptors	O
was	O
observed	O
later	O
than	O
in	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
.	O

At	O
3h	O
and	O
12h	O
post	O
-	O
Poly	O
I	O
:	O
C	O
injection	O
we	O
did	O
not	O
observe	O
differences	O
in	O
TLR3	B-GP
expression	O
when	O
compared	O
to	O
PBS	O
controls	O
.	O

Inflammatory	O
mediators	O
elicited	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
were	O
also	O
evaluated	O
in	O
peripheral	O
blood	O
.	O

Concentration	O
of	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
MCP1	B-GP
was	O
significantly	O
higher	O
3h	O
after	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
than	O
in	O
controls	O
(	O
Figure	O
5	O
),	O
while	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12p70	I-GP
and	O
IFNγ	B-GP
did	O
not	O
show	O
changes	O
in	O
poly	O
I	O
:	O
C	O
-	O
stimulated	O
mice	B-OG
versus	O
PBS	O
controls	O
(	O
data	O
not	O
shown	O
).	O

Altogether	O
these	O
results	O
suggest	O
a	O
systemic	O
pro	O
-	O
inflammatory	O
state	O
.	O

Poly	O
I	O
:	O
C	O
generates	O
a	O
proinflammatory	O
response	O
and	O
induces	O
RIG	B-GP
-	I-GP
I	I-GP
and	O
MDA5	B-GP
mRNA	O
expression	O
in	O
the	O
small	O
intestine	O
from	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Real	O
Time	O
-	O
PCR	O
analysis	O
of	O
the	O
IFNβ	B-GP
,	O
CXCL10	B-GP
,	O
TLR3	B-GP
,	O
MDA5	B-GP
,	O
and	O
RIG	B-GP
-	I-GP
I	I-GP
mRNA	O
expression	O
at	O
3	O
and	O
12	O
h	O
post	O
-	O
treatment	O
with	O
poly	O
I	O
:	O
C	O
(	O
black	O
bar	O
)	O
or	O
PBS	O
(	O
white	O
bar	O
).	O

All	O
values	O
were	O
normalized	O
to	O
the	O
housekeeping	O
mRNA	O
expression	O
(	O
HPRT	B-GP
).	O

All	O
results	O
were	O
expressed	O
as	O
a	O
fold	O
increase	O
of	O
PBS	O
and	O
poly	O
I	O
:	O
C	O
treatment	O
versus	O
the	O
mean	O
of	O
PBS	O
treatment	O
in	O
every	O
time	O
point	O
(	O
2	O
−	O
ΔΔCt	O
).	O

Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
versus	O
PBS	O
control	O
in	O
the	O
same	O
time	O
point	O
.	O

Increased	O
serum	O
levels	O
of	O
TNFα	B-GP
,	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
and	O
IL	B-GP
-	I-GP
6	I-GP
after	O
intraluminal	O
poly	O
I	O
:	O
C	O
administration	O
.	O

TNFα	B-GP
,	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
and	O
IL	B-GP
-	I-GP
6	I-GP
concentration	O
was	O
assessed	O
in	O
serum	O
after	O
3h	O
of	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
treatment	O
,	O
using	O
a	O
cytometric	O
bead	O
array	O
inflammation	O
kit	O
.	O

The	O
dotted	O
line	O
represents	O
the	O
limit	O
of	O
detection	O
.	O

Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

Intraluminal	O
poly	O
I	O
:	O
C	O
and	O
oral	O
dietary	O
antigen	O
induce	O
prolonged	O
enteropathy	B-DS
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG

Once	O
we	O
had	O
determined	O
the	O
local	O
and	O
systemic	O
immune	O
responses	O
of	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
to	O
mucosally	O
-	O
administered	O
poly	O
I	O
:	O
C	O
,	O
we	O
evaluated	O
whether	O
this	O
was	O
potentiated	O
or	O
prolonged	O
by	O
oral	O
administration	O
of	O
relevant	O
dietary	O
antigen	O
.	O

NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
were	O
treated	O
with	O
poly	O
I	O
:	O
C	O
and	O
fed	O
gliadin	B-GP
or	O
a	O
gluten	B-GP
-	O
free	O
chow	O
,	O
starting	O
24h	O
later	O
,	O
three	O
times	O
a	O
week	O
during	O
two	O
weeks	O
.	O

Small	O
intestinal	O
sections	O
and	O
blood	O
samples	O
were	O
collected	O
after	O
two	O
weeks	O
.	O

A	O
gluten	B-GP
-	O
free	O
chow	O
did	O
not	O
affect	O
the	O
level	O
of	O
enteropathy	B-DS
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
.	O

H	O
&	O
E	O
staining	O
showed	O
subepithelial	O
edema	O
and	O
moderate	O
lifting	O
of	O
villi	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
with	O
or	O
without	O
gliadin	B-GP
(	O
Figure	O
6A	O
).	O
Histological	O
parameters	O
revealed	O
that	O
both	O
groups	O
had	O
an	O
altered	O
V	O
/	O
C	O
ratio	O
,	O
but	O
similar	O
IELs	O
counts	O
,	O
2	O
weeks	O
after	O
poly	O
I	O
:	O
C	O
administration	O
(	O
Figure	O
6B	O
).	O

However	O
,	O
persistent	O
morphological	O
changes	O
in	O
the	O
small	O
intestinal	O
mucosa	O
were	O
only	O
observed	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
that	O
were	O
subsequently	O
challenged	O
with	O
gliadin	B-GP
,	O
indicating	O
maintenance	O
of	O
intestinal	O
damage	O
by	O
oral	O
antigen	O
administration	O
.	O

Gliadin	B-GP
induces	O
histological	O
damage	O
in	O
intraluminal	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

Representative	O
H	O
&	O
E	O
-	O
stained	O
sections	O
of	O
the	O
proximal	O
small	O
intestine	O
from	O
PBS	O
and	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
on	O
a	O
gluten	B-GP
free	O
diet	O
(	O
GFD	O
)	O
or	O
orally	O
gavaged	O
with	O
gliadin	B-GP
during	O
2	O
weeks	O
(	O
A	O
).	O

Morphological	O
analysis	O
of	O
small	O
intestine	O
from	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
treated	O
with	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
under	O
a	O
gluten	B-GP
free	O
diet	O
(	O
GFD	O
)	O
or	O
gavaged	O
with	O
gliadin	B-GP
during	O
2	O
weeks	O
:	O
V	O
/	O
C	O
ratio	O
,	O
number	O
of	O
IELs	O
and	O
histological	O
score	O
.	O

Stats	O
:	O
N	O
=	O
4	O
-	O
5	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
(	O
B	O
).	O

We	O
also	O
evaluated	O
intestinal	O
barrier	O
function	O
by	O
Ussing	O
chamber	O
technique	O
.	O

Oral	O
gavage	O
of	O
gliadin	B-GP
for	O
two	O
weeks	O
was	O
associated	O
with	O
increased	O
transepithelial	O
conductance	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

This	O
change	O
was	O
not	O
observed	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
fed	O
a	O
gluten	B-GP
free	O
chow	O
or	O
in	O
control	O
mice	B-OG
(	O
Figure	O
7A	O
).	O
The	O
evaluation	O
of	O
isotopic	O
flux	O
of	O
51Cr	O
-	O
EDTA	O
showed	O
increased	O
paracellular	O
permeability	O
two	O
weeks	O
after	O
poly	O
I	O
:	O
C	O
treatment	O
regardless	O
of	O
the	O
diet	O
.	O

However	O
the	O
percentage	O
increase	O
was	O
higher	O
in	O
mice	B-OG
receiving	O
gliadin	B-GP
gavages	O
than	O
in	O
those	O
on	O
gluten	B-GP
-	O
free	O
chow	O
(	O
mean	O
value	O
for	O
each	O
treatment	O
:	O
PBS	O
-	O
GFD	O
:	O
0	O
.	O
095	O
%,	O
poly	O
I	O
:	O
C	O
-	O
GFD	O
:	O
0	O
.	O
22	O
%,	O
PBS	O
-	O
gliadin	B-GP
:	O
0	O
,	O
17	O
%,	O
poly	O
I	O
:	O
C	O
-	O
Gliadin	B-GP
:	O
0	O
,	O
56	O
%	O
Hot	O
/	O
h	O
/	O
cm2	O
).	O

The	O
levels	O
of	O
the	O
proinflammatory	O
cytokines	B-GP
IL	B-GP
-	I-GP
12p70	I-GP
and	O
TNFα	B-GP
were	O
increased	O
in	O
peripheral	O
blood	O
of	O
mice	B-OG
gavaged	O
with	O
gliadin	B-GP
after	O
2	O
weeks	O
compared	O
with	O
those	O
on	O
gluten	B-GP
free	O
chow	O
,	O
even	O
in	O
the	O
absence	O
of	O
poly	O
I	O
:	O
C	O
treatment	O
(	O
Figure	O
7B	O
).	O

However	O
no	O
differences	O
were	O
observed	O
in	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IFNγ	B-GP
cytokine	B-GP
production	O
in	O
any	O
of	O
groups	O
(	O
data	O
not	O
shown	O
).	O

Gliadin	B-GP
gavages	O
also	O
induced	O
an	O
increment	O
in	O
the	O
anti	O
-	O
inflammatory	O
cytokine	B-GP
IL	B-GP
-	I-GP
10	I-GP
in	O
serum	O
.	O

Remarkably	O
,	O
poly	O
I	O
:	O
C	O
treatment	O
abolished	O
the	O
production	O
of	O
IL	B-GP
-	I-GP
10	I-GP
induced	O
by	O
gliadin	B-GP
.	O

Therefore	O
,	O
orally	O
delivered	O
gliadin	B-GP
in	O
poly	O
I	O
:	O
C	O
treated	O
mice	B-OG
produced	O
a	O
substantial	O
imbalance	O
in	O
the	O
IL	B-GP
-	I-GP
12p70	I-GP
/	O
IL	B-GP
-	I-GP
10	I-GP
ratio	O
,	O
suggesting	O
a	O
long	O
lasting	O
proinflammatory	O
milieu	O
.	O

Serum	O
levels	O
of	O
IL	B-GP
-	I-GP
12p70	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
were	O
below	O
the	O
limit	O
of	O
detection	O
in	O
mice	B-OG
on	O
gluten	B-GP
-	O
free	O
chow	O
.	O

These	O
results	O
suggest	O
that	O
local	O
inflammatory	O
and	O
functional	O
processes	O
in	O
the	O
small	O
intestine	O
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
predispose	O
to	O
stronger	O
functional	O
impairment	O
and	O
inflammatory	O
response	O
to	O
a	O
relevant	O
orally	O
-	O
administered	O
dietary	O
antigen	O
.	O

Gliadin	B-GP
induces	O
barrier	O
dysfunction	O
and	O
proinflammatory	O
cytokines	B-GP
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

After	O
24h	O
of	O
the	O
final	O
gavage	O
,	O
sections	O
of	O
small	O
intestine	O
were	O
mounted	O
in	O
Ussing	O
chambers	O
and	O
tissue	O
conductance	O
(	O
mS	O
/	O
cm2	O
)	O
and	O
isotopic	O
flux	O
(%	O
Hot	O
/	O
h	O
/	O
cm2	O
)	O
were	O
measured	O
.	O

Each	O
dot	O
represents	O
an	O
individual	O
mouse	B-OG
and	O
is	O
a	O
mean	O
of	O
2	O
independent	O
tissues	O
.	O

Stats	O
:	O
N	O
=	O
3	O
-	O
4	O
mice	B-OG
per	O
group	O
,	O
Two	O
way	O
ANOVA	O
and	O
Bonferroni	O
post	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
(	O
A	O
).	O

Analysis	O
of	O
IL	B-GP
-	I-GP
12p70	I-GP
,	O
TNFα	B-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
in	O
serum	O
samples	O
from	O
poly	O
I	O
:	O
C	O
or	O
PBS	O
-	O
treated	O
mice	B-OG
on	O
a	O
gluten	B-GP
-	O
free	O
diet	O
(	O
GFD	O
)	O
or	O
gavaged	O
with	O
gliadin	B-GP
for	O
2	O
weeks	O
.	O

IL	B-GP
-	I-GP
12p70	I-GP
/	O
IL	B-GP
-	I-GP
10	I-GP
ratio	O
was	O
determined	O
.	O

Serum	O
concentration	O
of	O
cytokines	B-GP
was	O
determined	O
by	O
a	O
cytometric	O
bead	O
array	O
inflammation	O
kit	O
.	O

The	O
dotted	O
line	O
represents	O
the	O
limit	O
of	O
detection	O
.	O

Stats	O
:	O
N	O
=	O
4	O
-	O
5	O
mice	B-OG
per	O
group	O
,	O
Two	O
way	O
ANOVA	O
and	O
Bonferroni	O
post	O
-	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
gliadin	B-GP
versus	O
GFD	O
mice	B-OG
;	O
#	O
P	O
<	O
0	O
.	O
05	O
poly	O
I	O
:	O
C	O
versus	O
PBS	O
in	O
Gliadin	B-GP
-	O
gavaged	O
mice	B-OG
(	O
B	O
).	O

Discussion	O

We	O
showed	O
that	O
induction	O
of	O
local	O
small	O
intestinal	O
inflammation	O
can	O
be	O
elicited	O
by	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
to	O
both	O
wild	O
type	O
and	O
gliadin	B-GP
-	O
sensitive	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

We	O
determined	O
that	O
the	O
severe	O
enteropathy	B-DS
induced	O
by	O
intraluminal	O
poly	O
I	O
:	O
C	O
,	O
predisposed	O
to	O
functional	O
impairment	O
of	O
small	O
intestine	O
in	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
receiving	O
the	O
dietary	O
antigen	O
,	O
gliadin	B-GP
.	O

During	O
viral	O
enteric	O
infections	B-DS
,	O
intermediates	O
of	O
replication	O
,	O
such	O
as	O
dsRNA	O
,	O
are	O
produced	O
in	O
infected	O
cells	O
[	O
6	O
]	O
and	O
trigger	O
a	O
rapid	O
inflammatory	O
cascade	O
,	O
which	O
involves	O
the	O
activation	O
of	O
TLR3	B-GP
and	O
RNA	B-GP
helicases	I-GP
such	O
as	O
RIG	B-GP
-	I-GP
I	I-GP
and	O
MDA5	B-GP
[	O
7	O
].	O

Poly	O
I	O
:	O
C	O
is	O
a	O
synthetic	O
analogue	O
commonly	O
used	O
to	O
mimic	O
the	O
effects	O
of	O
dsRNA	O
which	O
causes	O
intestinal	O
pathology	O
when	O
injected	O
parentally	O
[	O
2	O
],	O
[	O
3	O
],	O
[	O
4	O
].	O

The	O
marked	O
villus	O
shortening	O
and	O
increased	O
enterocyte	O
apoptosis	O
observed	O
after	O
parenteral	O
poly	O
I	O
:	O
C	O
has	O
been	O
suggested	O
to	O
be	O
caused	O
by	O
TLR3	B-GP
/	O
TRIF	B-GP
/	O
Caspase	B-GP
8	I-GP
activation	O
[	O
5	O
].	O

We	O
used	O
instead	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
and	O
demonstrated	O
it	O
produced	O
severe	O
intestinal	O
pathology	O
,	O
as	O
assessed	O
by	O
reduced	O
V	O
/	O
C	O
ratio	O
,	O
increased	O
IELs	O
counts	O
and	O
increased	O
global	O
histological	O
scores	O
.	O

Induction	O
of	O
dsRNA	O
sensors	O
TLR3	B-GP
,	O
MDA5	B-GP
and	O
RIG	B-GP
-	I-GP
I	I-GP
was	O
transient	O
,	O
peaked	O
at	O
6h	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
12h	O
.	O

In	O
previous	O
models	O
using	O
parenteral	O
poly	O
I	O
:	O
C	O
administration	O
,	O
mucosal	O
damage	O
seemed	O
to	O
be	O
specific	O
for	O
TLR3	B-GP
activation	O
[	O
3	O
],	O
[	O
4	O
],	O
[	O
5	O
].	O

The	O
underlying	O
mechanisms	O
proposed	O
for	O
intestinal	O
damage	O
include	O
NK	O
cells	O
[	O
2	O
]	O
and	O
CD8αα	B-GP
+	O
IELs	O
with	O
critical	O
participation	O
of	O
IL	B-GP
-	I-GP
15	I-GP
[	O
3	O
],	O
[	O
4	O
].	O

A	O
recent	O
study	O
however	O
has	O
proposed	O
that	O
,	O
neither	O
NK	O
cells	O
,	O
IELs	O
or	O
IL	B-GP
-	I-GP
15	I-GP
are	O
involved	O
in	O
the	O
induction	O
of	O
intestinal	O
pathology	O
[	O
5	O
].	O

Using	O
intraluminal	O
poly	O
I	O
:	O
C	O
,	O
we	O
found	O
a	O
strong	O
and	O
early	O
increase	O
of	O
IFNβ	B-GP
mRNA	O
levels	O
in	O
the	O
small	O
intestine	O
of	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
2h	O
post	O
-	O
treatment	O
,	O
indicating	O
a	O
mucosal	O
specific	O
poly	O
I	O
:	O
C	O
-	O
signaling	O
activation	O
.	O

TNFα	B-GP
,	O
a	O
cytokine	B-GP
commonly	O
involved	O
in	O
the	O
early	O
inflammatory	O
response	O
,	O
was	O
also	O
transiently	O
upregulated	O
.	O

Remarkably	O
,	O
a	O
60	O
-	O
fold	O
increase	O
in	O
CXCL10	B-GP
expression	O
was	O
observed	O
4h	O
after	O
intraluminal	O
poly	O
I	O
:	O
C	O
.	O

CXCL10	B-GP
has	O
previously	O
been	O
shown	O
to	O
be	O
upregulated	O
by	O
poly	O
I	O
:	O
C	O
in	O
different	O
experimental	O
strategies	O
[	O
23	O
],	O
and	O
it	O
may	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
small	O
intestine	O
pathology	O
since	O
it	O
is	O
a	O
major	O
chemo	O
-	O
attractant	O
for	O
Th1	O
CXCR3	B-GP
+	O
cells	O
into	O
inflamed	O
tissues	O
[	O
24	O
],	O
[	O
25	O
].	O

The	O
mRNA	O
expression	O
of	O
proinflammatory	O
cytokines	B-GP
such	O
as	O
IL	B-GP
-	I-GP
15	I-GP
,	O
IL	B-GP
-	I-GP
18	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IFNγ	B-GP
,	O
chemokines	B-GP
such	O
as	O
MCP1	B-GP
and	O
CXCL2	B-GP
and	O
anti	O
-	O
and	O
pro	O
-	O
apoptotic	O
molecules	O
as	O
Bcl	B-GP
-	I-GP
2	I-GP
and	O
Bax	B-GP
respectively	O
,	O
were	O
analyzed	O
,	O
but	O
no	O
changes	O
were	O
observed	O
(	O
data	O
not	O
shown	O
).	O

This	O
is	O
consistent	O
with	O
the	O
report	O
by	O
McAllister	O
C	O
.	O
et	O
al	O
.	O
[	O
5	O
]	O
using	O
a	O
parenteral	O
poly	O
I	O
:	O
C	O
model	O
.	O

Since	O
poly	O
I	O
:	O
C	O
triggers	O
a	O
cascade	O
of	O
inflammatory	O
reactions	O
involving	O
different	O
signaling	O
pathways	O
some	O
of	O
the	O
effects	O
after	O
poly	O
I	O
:	O
C	O
administration	O
may	O
also	O
have	O
diverse	O
origins	O
.	O

The	O
observation	O
that	O
transglutaminase	B-GP
2	I-GP
(	O
TG2	B-GP
)	O
is	O
activated	O
in	O
small	O
intestine	O
by	O
intraperitoneal	O
poly	O
I	O
:	O
C	O
administration	O
highlights	O
that	O
different	O
players	O
may	O
contribute	O
to	O
additional	O
dysregulation	O
of	O
gut	O
homeostasis	O
[	O
26	O
].	O

Upregulation	O
of	O
TG2	B-GP
has	O
also	O
been	O
related	O
to	O
NFkB	B-GP
pathway	O
,	O
driving	O
an	O
amplification	O
loop	O
of	O
inflammation	O
and	O
damage	O
at	O
the	O
small	O
intestinal	O
mucosa	O
[	O
27	O
].	O

Overall	O
our	O
results	O
suggest	O
that	O
intraluminal	O
poly	O
I	O
:	O
C	O
induces	O
rapid	O
mucosal	O
immune	O
activation	O
involving	O
IFNβ	B-GP
,	O
and	O
the	O
CXCL10	B-GP
/	O
CXCR3	B-GP
axis	O
that	O
may	O
drive	O
inflammation	O
towards	O
a	O
Th1	O
profile	O
.	O

Understanding	O
the	O
early	O
and	O
delayed	O
consequences	O
of	O
immune	O
activation	O
by	O
enteric	O
viral	B-DS
infections	I-DS
,	O
or	O
dsRNA	O
,	O
has	O
important	O
implications	O
for	O
post	O
-	O
infectious	O
inflammatory	O
and	O
functional	O
consequences	O
[	O
10	O
].	O

Thus	O
our	O
second	O
aim	O
was	O
to	O
determine	O
whether	O
a	O
single	O
intraluminal	O
administration	O
of	O
poly	O
I	O
:	O
C	O
influenced	O
subsequent	O
responses	O
to	O
gliadin	B-GP
,	O
a	O
dietary	O
antigen	O
that	O
causes	O
CD	B-DS
in	O
genetically	O
susceptible	O
people	O
,	O
but	O
which	O
may	O
be	O
involved	O
in	O
gut	O
functional	O
abnormalities	O
in	O
a	O
subgroup	O
of	O
patients	O
with	O
irritable	B-DS
bowel	I-DS
syndrome	I-DS
(	O
non	B-DS
celiac	I-DS
gluten	I-DS
sensitivity	I-DS
)	O
[	O
28	O
].	O

For	O
this	O
we	O
used	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
,	O
which	O
lack	O
all	O
endogenous	O
class	O
II	O
molecules	O
and	O
express	O
the	O
human	B-OG
HLA	B-GP
-	O
DQ8	O
gene	O
involved	O
in	O
CD	B-DS
[	O
16	O
],	O
[	O
29	O
].	O

Previous	O
studies	O
using	O
this	O
model	O
have	O
shown	O
that	O
gliadin	B-GP
sensitization	O
results	O
in	O
barrier	O
dysfunction	O
and	O
moderate	O
enteropathy	B-DS
[	O
15	O
].	O

Poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
developed	O
mucosal	O
damage	O
characterized	O
by	O
higher	O
histological	O
score	O
than	O
in	O
control	O
mice	B-OG
,	O
cell	O
infiltration	O
in	O
LP	O
,	O
reduction	O
of	O
V	O
/	O
C	O
ratio	O
,	O
increased	O
IEL	O
counts	O
,	O
and	O
upregulation	O
of	O
IFNβ	B-GP
and	O
CXCL10	B-GP
mRNA	O
in	O
intestinal	O
mucosa	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
higher	O
levels	O
of	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
MCP1	B-GP
in	O
peripheral	O
blood	O
.	O

After	O
poly	O
I	O
:	O
C	O
administration	O
,	O
one	O
group	O
of	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
was	O
subjected	O
to	O
oral	O
gliadin	B-GP
challenges	O
while	O
another	O
was	O
fed	O
a	O
gluten	B-GP
free	O
chow	O
.	O
51Cr	O
-	O
EDTA	O
flux	O
studies	O
indicated	O
increased	O
paracellular	O
permeability	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
after	O
two	O
weeks	O
regardless	O
of	O
the	O
dietary	O
treatments	O
.	O

Poly	O
I	O
:	O
C	O
also	O
induced	O
alterations	O
in	O
V	O
/	O
C	O
ratio	O
compared	O
to	O
control	O
mice	B-OG
in	O
both	O
gliadin	B-GP
challenged	O
and	O
gluten	B-GP
free	O
mice	B-OG
.	O

However	O
,	O
only	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
receiving	O
gliadin	B-GP
presented	O
higher	O
global	O
histological	O
scores	O
,	O
demonstrating	O
severe	O
changes	O
in	O
the	O
mucosa	O
.	O

More	O
importantly	O
,	O
increased	O
transepithelial	O
conductance	O
was	O
only	O
observed	O
in	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
that	O
were	O
subsequently	O
challenged	O
with	O
gliadin	B-GP
.	O

Remarkably	O
,	O
after	O
two	O
weeks	O
of	O
gliadin	B-GP
ingestion	O
,	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
showed	O
increased	O
levels	O
of	O
the	O
proinflammatory	O
cytokines	B-GP
IL	B-GP
-	I-GP
12p70	I-GP
and	O
TNFα	B-GP
in	O
peripheral	O
blood	O
,	O
compared	O
with	O
those	O
on	O
gluten	B-GP
-	O
free	O
chow	O
,	O
indicating	O
a	O
causal	O
link	O
to	O
gliadin	B-GP
challenges	O
and	O
not	O
to	O
poly	O
I	O
:	O
C	O
treatment	O
.	O

Moreover	O
,	O
IL	B-GP
-	I-GP
10	I-GP
induction	O
by	O
gliadin	B-GP
,	O
a	O
feature	O
observed	O
in	O
-	O
DQ8	O
mouse	B-OG
models	O
of	O
gluten	B-GP
sensitivity	O
before	O
[	O
15	O
],	O
[	O
30	O
],	O
[	O
31	O
],	O
was	O
inhibited	O
in	O
previously	O
poly	O
I	O
:	O
C	O
-	O
treated	O
mice	B-OG
.	O

An	O
imbalance	O
in	O
the	O
IL	B-GP
-	I-GP
12p70	I-GP
/	O
IL	B-GP
-	I-GP
10	I-GP
ratio	O
was	O
observed	O
in	O
gliadin	B-GP
challenged	O
and	O
poly	O
I	O
:	O
C	O
-	O
treated	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O

The	O
inflammatory	O
effects	O
elicited	O
by	O
IL	B-GP
-	I-GP
12p70	I-GP
and	O
TNFα	B-GP
have	O
been	O
shown	O
to	O
have	O
direct	O
effects	O
on	O
barrier	O
function	O
and	O
intestinal	O
damage	O
.	O

The	O
correct	O
assembly	O
of	O
tight	O
junction	O
components	O
is	O
critical	O
to	O
preserve	O
barrier	O
integrity	O
and	O
TNFα	B-GP
is	O
recognised	O
as	O
one	O
of	O
the	O
main	O
mediators	O
associated	O
with	O
inflammation	O
in	O
Crohn	B-DS
'	I-DS
s	I-DS
disease	I-DS
and	O
CD	B-DS
.	O

TNFα	B-GP
signalling	O
activates	O
myosin	B-GP
light	I-GP
chain	I-GP
kinase	I-GP
(	O
MLCK	B-GP
)	O
and	O
tight	O
junction	O
remodelling	O
leading	O
to	O
loss	O
of	O
barrier	O
function	O
[	O
32	O
],	O
[	O
33	O
].	O

It	O
is	O
noteworthy	O
that	O
gliadin	B-GP
peptides	O
can	O
also	O
increase	O
permeability	O
by	O
innate	O
mechanisms	O
amplifying	O
the	O
circuit	O
of	O
mucosal	O
damage	O
[	O
34	O
],	O
[	O
35	O
],	O
[	O
36	O
],	O
[	O
37	O
].	O

We	O
did	O
not	O
observe	O
changes	O
in	O
IL	B-GP
-	I-GP
15	I-GP
expression	O
associated	O
with	O
this	O
model	O
.	O

IL	B-GP
-	I-GP
15	I-GP
expression	O
has	O
a	O
complex	O
post	O
-	O
transcriptional	O
control	O
which	O
is	O
particularly	O
important	O
to	O
maintain	O
an	O
adequate	O
balance	O
of	O
the	O
immune	O
response	O
in	O
gut	O
.	O

Remarkably	O
,	O
IL	B-GP
-	I-GP
15	I-GP
expression	O
has	O
been	O
shown	O
to	O
be	O
modulated	O
by	O
p31	O
-	O
43	O
gliadin	B-GP
peptide	O
,	O
which	O
triggers	O
different	O
innate	O
responses	O
in	O
Caco	O
-	O
2	O
cells	O
as	O
well	O
as	O
in	O
human	B-OG
duodenum	O
[	O
38	O
].	O

Though	O
we	O
did	O
not	O
specifically	O
work	O
with	O
p31	O
-	O
43	O
,	O
we	O
have	O
performed	O
significant	O
characterization	O
of	O
the	O
NOD	O
-	O
DQ8	O
model	O
[	O
15	O
].	O
Given	O
the	O
NOD	O
background	O
of	O
mice	B-OG
this	O
model	O
is	O
not	O
specifically	O
IL	B-GP
-	I-GP
15	I-GP
driven	O
.	O

Thus	O
,	O
neither	O
mRNA	O
nor	O
protein	O
IL	B-GP
-	I-GP
15	I-GP
determinations	O
in	O
this	O
particular	O
model	O
are	O
useful	O
markers	O
.	O

In	O
conclusion	O
,	O
intraluminal	O
poly	O
I	O
:	O
C	O
induced	O
a	O
severe	O
but	O
transitory	O
damage	O
in	O
the	O
small	O
intestinal	O
mucosa	O
in	O
both	O
wild	O
-	O
type	O
and	O
NOD	B-OG
-	I-OG
DQ8	I-OG
mice	I-OG
.	O
The	O
combination	O
of	O
poly	O
I	O
:	O
C	O
and	O
subsequent	O
gliadin	B-GP
feeding	O
in	O
the	O
genetically	O
susceptible	O
mouse	B-OG
strain	O
NOD	O
-	O
DQ8	O
,	O
led	O
to	O
a	O
proinflammatory	O
synergistic	O
effect	O
and	O
impairment	O
of	O
gut	O
barrier	O
function	O
.	O

Our	O
results	O
raise	O
the	O
intriguing	O
hypothesis	O
thattype	O
I	O
IFNs	O
constitute	O
an	O
important	O
contributor	O
to	O
the	O
loss	O
of	O
tolerance	O
to	O
dietary	O
antigens	O
such	O
as	O
gluten	B-GP
,	O
after	O
a	O
viral	B-DS
infection	I-DS
.	O

This	O
may	O
be	O
particularly	O
important	O
in	O
genetically	O
susceptible	O
hosts	O
,	O
by	O
promoting	O
inflammation	O
as	O
well	O
as	O
a	O
biased	O
Th1	O
response	O
.	O

We	O
hypothesize	O
that	O
this	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
for	O
the	O
clinical	O
link	O
between	O
enteric	O
infections	B-DS
and	O
post	O
-	O
inflammatory	O
and	O
functional	O
disorders	O
[	O
11	O
],	O
[	O
12	O
],	O
[	O
39	O
],	O
[	O
40	O
],	O
[	O
41	O
].	O

Supporting	O
Information	O

Different	O
molecular	O
weight	O
poly	O
I	O
:	O
Cs	O
cause	O
enteropathy	B-DS
.	O

Analysis	O
of	O
different	O
molecular	O
weight	O
poly	O
I	O
:	O
Cs	O
by	O
ethidium	O
bromide	O
-	O
stained	O
agarose	O
gel	O
electrophoresis	O
,	O
commercial	O
poly	O
I	O
:	O
C	O
(	O
PICs	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
PICL	O
(	O
LMW	O
-	O
PIC	O
)	O
and	O
PICH	O
(	O
HMW	O
-	O
PIC	O
)	O
(	O
Invivogen	O
)	O
(	O
A	O
).	O

Morphological	O
analysis	O
performed	O
in	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
intraluminally	O
treated	O
with	O
PICs	O
,	O
PICL	O
or	O
PICH	O
in	O
a	O
time	O
-	O
course	O
experiment	O
(	O
from	O
12	O
up	O
to	O
72hs	O
)	O
(	O
B	O
):	O
V	O
/	O
C	O
ratio	O
vs	O
.	O
time	O
(	O
i	O
);	O
V	O
/	O
C	O
ratio	O
at	O
72h	O
post	O
-	O
treatment	O
with	O
different	O
poly	O
I	O
:	O
Cs	O
or	O
PBS	O
(	O
ii	O
);	O
Histological	O
score	O
at	O
12h	O
and	O
72h	O
after	O
different	O
poly	O
I	O
:	O
Cs	O
treatments	O
(	O
iii	O
).	O

(	O
Stats	O
:	O
N	O
=	O
4	O
mice	B-OG
per	O
group	O
,	O
Unpaired	O
t	O
test	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
).	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

